Journal article
In vitro effect of amantadine and interferon α-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus-infected patients
Antiviral research, v 42(1), pp 59-70
May 1999
PMID: 10333143
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
The effects of amantadine (1–5 μM) and interferon α (IFNα)-2a alone (1000 IU/ml) and combined, have been studied in cultured peripheral blood mononuclear cells (PBMC) from 15 chronic hepatitis C patients and ten healthy donors. Amantadine itself did not affect cell viability and had minor effects on the response to mitogens by PBMC. Four patients (27%), but no donors, had hepatitis C virus (HCV) core and NS3-specific proliferative responses. Amantadine suppressed these responses in all cases and its antiproliferative effect was greater than that of IFNα (Mann–Whitney’s
U-test:
P<0.05 in both cases). All PBMC cultures from patients, but none from donors, were HCV RNA positive. Amantadine alone or combined with IFNα dose-dependently reduced HCV RNA content in individual PBMC (Wilcoxon’s signed rank test: 1 μM,
P<0.05; 2 μM,
P<0.02; and 5 μM,
P=0.16) with respect to untreated cultures. In addition, 7, 13 and 20% of PBMC cultures became HCV RNA negative with 2 μM amantadine alone, IFNα alone and their combination, respectively. Finally, in contrast to IFNα, amantadine did not modify expression of 2′,5′-oligoadenylate synthetase activity or the spontaneous or mitogen-stimulated IFNγ and interleukin 10 production. In conclusion, these effects in PBMC from HCV patients suggest that the amantadine/IFNα combination might be considered a therapeutic option for treating chronic hepatitis C patients.
Metrics
Details
- Title
- In vitro effect of amantadine and interferon α-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus-infected patients
- Creators
- Julio Martı́n - Department of Hepatology, Fundación Jiménez Dı́az, Avda. Reyes Católicos, 2, 28040 Madrid, SpainMario Fernández - Hospital Universitario Fundación Jiménez DíazMiguel Rico - Fundación para el Estudio de las Hepatitis ViralesMargarita Pardo - Fundación para el Estudio de las Hepatitis ViralesJuan Antonio Quiroga - Hospital Universitario Fundación Jiménez DíazFriederike Zahm - RocheSonia Navas-Martin - Drexel University, Microbiology and ImmunologyVicente Carreño - Fundación para el Estudio de las Hepatitis Virales
- Publication Details
- Antiviral research, v 42(1), pp 59-70
- Publisher
- Elsevier
- Number of pages
- 12
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Microbiology and Immunology
- Web of Science ID
- WOS:000079924300006
- Scopus ID
- 2-s2.0-0032903035
- Other Identifier
- 991022047820004721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- International collaboration
- Web of Science research areas
- Pharmacology & Pharmacy
- Virology